Phaseline

Companies › Syndax Pharmaceuticals

Syndax Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 13 registered trials: 8 Phase 1, 3 Phase 2, 2 Phase 3; Respiratory, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
revumenib
Menin/Histone-lysine N-methyltransferase MLL inhibitor; Menin inhibitor
MEN1, KMT2APhase 3Acute Myeloid Leukemias; Acute Myeloid Leukemia; Acute Myeloid Leukemia, Adult; Recurrent Acute Leukemia of Ambiguous Lineage …Feb 2027
Axatilimab
Macrophage colony stimulating factor receptor inhibitor
CSF1RPhase 2Idiopathic Pulmonary Fibrosis; Chronic Graft-versus-host-diseaseNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06132256AxatilimabPhase 2Idiopathic Pulmonary FibrosisRespiratoryNov 2026
NCT06177067revumenibPhase 1Refractory Acute Myeloid LeukemiaOncologyJan 2027
NCT06222580revumenibPhase 1Acute Myeloid Leukemia With FLT3/ITD MutationOncologyJan 2027
NCT06226571revumenibPhase 1Acute Myeloid LeukemiasOncologyFeb 2027
NCT06313437revumenibPhase 1Acute Myeloid LeukemiaOncologyMar 2027
NCT04710576AxatilimabPhase 2Chronic Graft-versus-host-diseaseRespiratorySep 2027
NCT04065399revumenibPhase 1Acute Myeloid LeukemiaOncologyDec 2027
NCT05761171revumenibPhase 2Recurrent Acute Leukemia of Ambiguous LineageOncologyDec 2027
NCT05886049revumenibPhase 1Acute Myeloid LeukemiaOncologyDec 2027
NCT06575296revumenibPhase 1Acute LeukemiaOncologyApr 2028
NCT07356154revumenibPhase 1LeukemiaOncologyJan 2029
NCT07211958revumenibPhase 3Acute Myeloid LeukemiasOncologyJun 2029
NCT06652438revumenibPhase 3Acute Myeloid Leukemia, AdultOncologyDec 2029

From the company's SEC filings

Cash and short-term investments of $427m on 2026-09-30; operating cash outflow about $145m a year; runway about 35 months at that burn, to Sep 2029; 4 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CSF1R (1) MEN1 (1) KMT2A (1)

Companies with the same targets

Daiichi Sankyo SynOx Therapeutics Incyte Turning Point Therapeutics Deciphera Pharmaceuticals Merck KGaA Gossamer Bio USA Abbisko Therapeutics Qurient Xynomic Pharmaceuticals

Companies built like this

MiNK Therapeutics SPARK Biopharma NuvOx Olema Pharmaceuticals Celldex Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.